Recombinant TAG-72 (Minretumomab Biosimilar) antibody

Catalog No. ABIN7795096

The Humanized Monoclonal anti-TAG-72 (Minretumomab Biosimilar) antibody (ABIN7795096) specifically detects TAG-72 (Minretumomab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant TAG-72 (Minretumomab Biosimilar) antibody (ABIN7795096)

Target: TAG-72 (Minretumomab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This TAG-72 (Minretumomab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-TAG-72 (Minretumomab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Minretumomab Biosimilar, TAG-72 Monoclonal Antibody

Characteristics: Minretumomab Biosimilar uses the same protein sequences as the therapeutic antibody minretumomab. Minretumomab is a mouse monoclonal antibody that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers. A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric and humanized minretumomab, as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human TAG-72

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for TAG-72 (Minretumomab Biosimilar)

Target: TAG-72 (Minretumomab Biosimilar)

Alternative Name: Minretumomab Biosimilar

Target Type: Biosimilar